SCHEMBL6895790

SCHEMBL6895790

C[CH]OC(=O)Oc1ccccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PPARG P37231 1/20 0.43
BCHE P06276 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
NOTUM Q6P988 1/20 0.38
TSHR P16473 1/20 0.37
ACHE P22303 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236664 0.84 TDP1 (0.50) TDP1ATML3MBTL1PPARGBCHE
SCHEMBL29351165 0.84 TDP1 (0.50) TDP1ATML3MBTL1PPARGBCHE
SCHEMBL6890105 0.81 CA12 (0.48) ATML3MBTL1BCHEKDM4EHPGD
SCHEMBL25342703 0.80 FAAH (0.41) NPSR1KDM4EHPGDHSD17B10KMT2A
SCHEMBL6894273 0.79 L3MBTL1 (0.46) ATML3MBTL1KDM4EHPGDHSD17B10
SCHEMBL6886931 0.79 THRA (0.42) ATML3MBTL1NPSR1KDM4EHPGD
SCHEMBL6889852 0.79 TSHR (0.45) TDP1L3MBTL1PPARGHPGDHSD17B10
SCHEMBL6890294 0.79 L3MBTL1 (0.46) TDP1L3MBTL1NPSR1KDM4EHPGD
SCHEMBL1598495 0.79 HPGD (0.61) TDP1ATML3MBTL1PPARGBCHE
SCHEMBL6888142 0.77 ALDH1A1 (0.57) TDP1L3MBTL1BCHEKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 TDP1 3544/4885ATM 4611/4885L3MBTL1 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.